TY - JOUR
T1 - AN OPEN STUDY OF DEHYDROEPIANDROSTERONE IN SYSTEMIC LUPUS-ERYTHEMATOSUS
AU - van Vollenhoven, R. F.
AU - Engleman, E. G.
AU - McGuire, J. L.
PY - 1994
Y1 - 1994
N2 - Objective. To determine if dehydroepiandrosterone (DHEA) has clinical benefits in patients with systemic lupus erythematosus (SLE). Methods. Ten female patients with mild to moderate SLE and various disease manifestations were given DHEA (200 mg/day orally) for 3-6 months. The patients were given other medications as clinically indicated, and followed with respect to overall disease activity and specific outcome parameters. Results. After 3-6 months of DHEA treatment, indices for overall SLE activity including the SLEDAI (SLE Disease Activity Index) score and physician's overall assessment were improved, and corticosteroid requirements were decreased. Of 3 patients with significant proteinuria, 2 showed marked and 1 modest reductions in protein excretion. DHEA was well tolerated, the only frequently noted side effect being mild acneiform dermatitis. Conclusion. DHEA shows promise as a new therapeutic agent for the treatment of mild to moderate SLE. Further studies of DHEA in the treatment of SLE are warranted
AB - Objective. To determine if dehydroepiandrosterone (DHEA) has clinical benefits in patients with systemic lupus erythematosus (SLE). Methods. Ten female patients with mild to moderate SLE and various disease manifestations were given DHEA (200 mg/day orally) for 3-6 months. The patients were given other medications as clinically indicated, and followed with respect to overall disease activity and specific outcome parameters. Results. After 3-6 months of DHEA treatment, indices for overall SLE activity including the SLEDAI (SLE Disease Activity Index) score and physician's overall assessment were improved, and corticosteroid requirements were decreased. Of 3 patients with significant proteinuria, 2 showed marked and 1 modest reductions in protein excretion. DHEA was well tolerated, the only frequently noted side effect being mild acneiform dermatitis. Conclusion. DHEA shows promise as a new therapeutic agent for the treatment of mild to moderate SLE. Further studies of DHEA in the treatment of SLE are warranted
U2 - https://doi.org/10.1002/art.1780370906
DO - https://doi.org/10.1002/art.1780370906
M3 - Article
C2 - 7945493
SN - 0004-3591
VL - 37
SP - 1305
EP - 1310
JO - Arthritis and rheumatism
JF - Arthritis and rheumatism
IS - 9
ER -